For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022
Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions. Cancer patients in the U.S. could get some important new treatment options. Shares of the companies involved could put up big gains if the agency delivers the approval decisions investors are hoping for. Big FDA decisions coming up in the first quarter for Bristol Myers Squibb ( NYSE:BMY ) , Eli Lilly ( NYSE:LLY ) AstraZeneca ( NASDAQ:AZN ) , and Merck ( NYSE:MRK ) could send their share prices soaring. Here's what to look for. Image source: Getty Images. Bristol Myers Squibb: Relatlimab Shares of Bristol Myers Squibb have gained around 17% since hitting a 52-week low in November. An FDA approval for a new type of cancer immunotherapy could push this pharma stock even higher. In September, the FDA began a priority review of Bristol Myers Squibb's … [Read more...] about 3 Big FDA Approvals to Watch For in Q1 2022
There's a common expression in the investing community, which goes as follows: "It's a market of stocks, not a stock market." This essentially means that even with the financial markets at or near all-time highs as they are now, not all stocks have fared well. Pharma stock Amgen ( NASDAQ:AMGN ) is a perfect example. At its current share price of $204, the stock is just a touch above its 52-week low and a whopping 26% below its 52-week high. Let's look at whether you should interpret this recent poor stock performance as a buying opportunity or a sign to steer clear of Amgen. Image source: Getty Images. A solid third-quarter performance Amgen reported $6.7 billion in revenue during the third quarter, which equates to a 4.4% growth rate against the year-ago period. What led to Amgen's respectable performance? Given Amgen's diversified portfolio of more than two dozen drugs, there were quite a few moving parts affecting growth in the quarter. Legacy medications such … [Read more...] about Should You Buy This Giant Biotech Stock?
Stocks rarely go straight up. When they do, the uncommon occurrence is called a "parabolic move." In stock terminology, such as move is defined by a sudden and dramatic increase in buying volume, thereby causing the company's share price to rapidly rise in a manner that resembles a parabola. Oddly enough, this phenomenon has happened on a far more regular basis in 2021 than at any other time in the history of the U.S. stock market. The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition ( NASDAQ:DWAC ) and Phunware ( NASDAQ:PHUN ) . Last week, Digital World Acquisition's shares rose by as much as 1,500%. Phunware's shares, for their part, posted a jaw-dropping intraday high of over 2,000% during a single trading session last week. This week, it might be biotech 's turn at the parabolic-move game. Shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) and Ocugen ( NASDAQ:OCGN … [Read more...] about 2 Biotech Stocks That Could Go Parabolic This Week
The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate. Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason. 1. Amgen Biotech company Amgen ( NASDAQ:AMGN ) has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more. Image source: Getty Images. When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A … [Read more...] about Is It Time to Buy the Dow’s 3 Worst Performing Stocks This Year?
Biotech stocks haven't been at their best of late. The SPDR S&P Biotech Exchange Traded Fund ( NYSEMKT:XBI ) has lost more than 30% of its value over the prior 12 months. The XBI is thus bumping up against its 52-week low as of this writing. Investors have been backing away from biotech stocks over the past year for many reasons, including inflationary pressures, the risk of rising interest rates, the threat of fundamental drug pricing reform in the U.S., and the appeal of other high-growth asset classes like cryptocurrency. All isn't lost, however. Biotech, as a whole, is still going through an unprecedented period of innovation. As a result, scores of untapped, high-value therapeutic markets are starting to open up, a fact that bodes well for the industry's long-term fortunes. Savvy investors, in turn, would be wise to take advantage of this broad selloff in biotech. Which biotech stocks are the most attractive buys amid this turmoil? Here are my top three biotech … [Read more...] about My 3 Top Biotech Stock Picks for 2022
Dividends can be a great source of passive income, and they can also help supercharge your portfolio's growth if you take advantage of automatic dividend reinvestment. In other words, no matter your investment style, dividend-paying stocks can help you reach your goals -- and one that looks like a particularly excellent option right now is Amgen ( NASDAQ:AMGN ) . AMGN data by YCharts Recent drug approvals will help boost top-line growth At first glance, Amgen's business doesn't look particularly strong. In the third quarter, its total revenue came in at $6.7 billion, representing a meager 4% year-over-year increase. One reason for that unimpressive growth is that some of its key products are now out of patent protection and facing off against biosimilars in the market. For instance, sales of Neulasta, which stimulates the production of infection-fighting white blood cells in cancer patients, decreased by 25% year over year in the third quarter to $415 million. … [Read more...] about 1 Top Dividend Stock to Buy and Hold in 2022 and Beyond
Pharmaceutical stocks are taking it on the chin right now. Underscoring this point, the SPDR S&P Biotech ETF , a top barometer of pharmaceutical investor sentiment, is down by a painful 22.1% year to date. The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022. Image source: Getty Images. 1. Adaptimmune Therapeutics Adaptimmune Therapeutics ( NASDAQ:ADAP ) , a cellular immunotherapy company, has so far lost 47.4% of its value relative to its 52-week high in 2021. The biotech's shares have cratered this year despite its lead product candidate, afami-cel, making significant strides toward a regulatory filing with the Food and Drug Administration (FDA) next year. Adaptimmunes's shares are thus … [Read more...] about 8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
Are some major acquisitions on the way in the biopharmaceutical industry this year? That remains to be seen. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. In this Motley Fool Live video recorded on Jan. 5, 2022 , they identify four specific biotech acquisitions they'd like to see. Keith Speights: Let's switch gears. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. There were a few, but not as many. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Brian Orelli: I'd like to see Bristol-Myers Squibb ( NYSE:BMY ) acquire Seagen ( NASDAQ:SGEN ) . I own Seagen. There would be some synergies on the commercial sales side. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. It could find some synergies in having salespeople sell just the same set of drugs … [Read more...] about 4 Biotech Acquisitions We’d Like to See in 2022
Investors have been taken on quite the ride over the past 21 months. They've navigated their way through the quickest decline of at least 30% in the history of the benchmark S&P 500 , and have reveled in what's become the strongest bounce back from a bear-market bottom on record. But in spite of the S&P 500 hitting more than five dozen all-time closing highs in 2021, bargains still abound for opportunistic investors. Even better, with most online brokerages doing away with minimum deposit requirements and trading commissions, any amount of money can be put to work and used to further your trek to financial independence -- even $100. If you have $100 that's ready to be invested in the market, which won't be needed for bills or emergencies, the following three no-brainer stocks would make for perfect buys right now. Image source: Getty Images. Western Digital Investors often think of growth stocks and value stocks as existing in their own realms. In other … [Read more...] about 3 No-Brainer Stocks to Invest $100 In Right Now